Overview
- WHO issued its first guideline conditionally recommending semaglutide, tirzepatide and liraglutide for long‑term obesity treatment in adults, to be used alongside diet, physical activity and counseling.
- WHO projected that fewer than 10% of those who could benefit will receive GLP‑1 therapies by 2030 without major shifts in pricing and manufacturing capacity.
- Australia’s Therapeutic Goods Administration updated all GLP‑1 product labels to note reports of depression and suicidal thoughts, citing 72 reports of suicidal ideation in its database while emphasizing that causation has not been established.
- The TGA advised users of tirzepatide (Mounjaro) to switch to non‑oral contraception or add a barrier method for four weeks after starting or each dose increase, as reduced effectiveness of oral contraceptives could not be ruled out.
- Manufacturers announced direct‑sale cuts to improve affordability, with Novo Nordisk pricing Ozempic and Wegovy from $349 per month and Eli Lilly reducing Zepbound to as low as $299, alongside ongoing efforts to expand coverage.